TP 1287

Drug Profile

TP 1287

Alternative Names: TP-1287

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Tolero Pharmaceuticals
  • Class Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 26 Jan 2017 Tolero Pharmaceuticals has been acquired by Sumitomo Dainippon Pharma
  • 29 Aug 2016 Preclinical trials in Solid tumours in USA (PO) before August 2016 (Tolero Pharmaceuticals pipeline; August 2016)
  • 09 Jun 2016 Tolero Pharmaceuticals plans to initiate a clinical trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top